Home
HelpTest Code CSMRT mSMART Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow
Specimen Required
Only orderable as a reflex. For more information see one of the following:
MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow
MSMRD / Myeloma Stratification and Risk-Adapted Therapy with Reflex to Minimal Residual Disease, Bone Marrow
Container/Tube:
Preferred: Yellow top (ACD solution A or B)
Acceptable: Lavender top (EDTA) or green top (heparin)
Specimen Volume: 4 mL
Collection Instructions:
1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. Do not aliquot.
Useful For
Risk stratification of patients with multiple myeloma, which can assist in determining treatment and management decisions
Sorting plasma cells for fluorescence in situ hybridization analysis
Risk stratification of patients with newly diagnosed multiple myeloma
Method Name
Only orderable as a reflex. For more information see one of the following:
MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow
MSMRD / Myeloma Stratification and Risk-Adapted Therapy with Reflex to Minimal Residual Disease, Bone Marrow
Flow Cytometric Cell Selection
Reporting Name
MPCDS Pre-Analysis Cell Sorting, BMSpecimen Type
Bone MarrowSpecimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Bone Marrow | Ambient (preferred) | 4 days |
| Refrigerated | 4 days |
Reject Due To
| Gross hemolysis | Reject |
| Fully clotted | Reject |
Clinical Information
Multiple myeloma is increasingly recognized as a disease characterized by marked cytogenetic, molecular, and proliferative heterogeneity. This heterogeneity is manifested clinically by varying degrees of disease aggressiveness. Multiple myeloma patients with more aggressive disease experience suboptimal responses to some therapeutic approaches; therefore, identifying these patients is critically important for selecting appropriate treatment options.
MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow classifies patients into either standard or high-risk categories based on the results of 2 assays: plasma cell proliferation and fluorescence in situ hybridization for specific multiple myeloma-associated abnormalities.
Reference Values
Only orderable as a reflex. see one of the following:
MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow
MSMRD / Myeloma Stratification and Risk-Adapted Therapy with Reflex to Minimal Residual Disease, Bone Marrow
An interpretive report will be provided.
Interpretation
Correlation with clinical, histopathologic and additional laboratory findings is required for final interpretation of these results. The final interpretation of results for clinical management of the patient is the responsibility of the managing physician.
Day(s) Performed
Specimens processed Monday through Sunday
Results reported Monday through Saturday
Report Available
1 to 11 daysSpecimen Retention Time
14 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88184-Flow Cytometry; first cell surface, cytoplasmic or nuclear marker
88185 x 5-Flow Cytometry, additional cell surface, cytoplasmic or nuclear marker (each)
LOINC Code Information
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 607682 | MPCDS Pre-Analysis Cell Sort | No LOINC Needed |
| 607688 | Final Diagnosis | No LOINC Needed |